Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected

Core Insights - Eli Lilly is set to release data from a late-stage trial of its weight loss drug retatrutide earlier than expected, later this year [1] - The company anticipates results from a study involving obesity and knee osteoarthritis patients in 2025, which was previously scheduled to conclude in February 2026 [2] - Retatrutide is a significant component of Eli Lilly's drug pipeline, potentially solidifying its leadership in the weight loss and diabetes treatment market against competitors like Novo Nordisk [3] Drug Mechanism and Efficacy - Retatrutide, known as the "triple G" drug, mimics three hunger-regulating hormones: GLP-1, GIP, and glucagon, leading to more effective appetite control and food satisfaction [3] - In a mid-stage trial, retatrutide resulted in an average weight loss of 24.2% (approximately 58 pounds) over 48 weeks, compared to a 2.1% loss in the placebo group [5] - Higher doses of Eli Lilly's tirzepatide have shown an average weight loss of up to 22.5% in late-stage studies, indicating strong competition in the weight loss drug market [4][5]